AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 153 min read$FATE

FATE THERAPEUTICS INC (FATE): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fate-ex10_1.htm EX-10.1 EX-10.1 FATE THERAPEUTICS, INC. THIRD AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option a

Original reporting
SEC EDGAR 8-K
Published Jun 15, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$FATE
Neutral
low confidence
Mentioned
$FATE
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FATENeutralLow
01

Why it matters

This type of disclosure can affect expectations for leadership stability and incentive alignment, but the excerpt does not provide the concrete personnel or compensation outcomes needed for a strong trading thesis.

02

Market read

Governance and compensation updates are disclosed via an 8-K; without the specific named changes/terms, the tradable signal is likely limited.

03

What to watch

Traders should focus on the specific individuals named in the 8-K (departures/elections) and any material award terms or employment agreements, which are not present in the provided excerpt.

Relevance 6/10Novelty 4/10Timing: Filed today (8-K on 2026-06-15)

Background

The filing is an SEC Form 8-K (Item 5.02 and Item 5.07) tied to director/officer changes and compensatory arrangements, with an attached stock option/incentive plan document excerpt.

Company-level read

Ticker impact

$FATENeutralLow confidence
Context

Fate Therapeutics files an 8-K for director/officer departures, director elections, and compensatory arrangements under Item 5.02.

Expected impact

Likely modest, sentiment-driven volatility around governance headlines; fundamental impact depends on who departed/was appointed and the compensation structure details not shown in the excerpt.

Evidence & confidence

The excerpt is largely boilerplate plan language and does not include the specific personnel changes or award terms that would drive a clearer valuation or risk read-through.

Market effects

Sector

No direct sector datapoint; governance/compensation updates are company-specific.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the changes are routine (e.g., scheduled board refresh) and compensation is standard, the market may largely ignore the filing beyond minor sentiment noise.

Key entities

  • company
    Fate Therapeutics, Inc.

    Subject of the 8-K filing covering director/officer changes and compensatory arrangements.

Read at source← All news

Related articles

AUG 14
$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

finanznachrichten.de4 min
AUG 13
$FATEMed

FATE THERAPEUTICS INC (FATE): Results of Operations and Financial Condition

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated

SEC EDGAR 8-K6 min
JUL 9
$FATEMedAI 8/10

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics (NASDAQ: FATE) said the FDA cleared its IND for FT839, an off-the-shelf dual CAR T-cell candidate targeting CD19 and CD38. The company plans a Phase 1/2 multi-indication basket trial starting in 2H 2026 to test FT839 with standard-of-care for autoimmune diseases, with or without conditioning chemotherapy. Key initial indications include rheumatoid arthritis and lupus.

manilatimes.net3 min
JUL 6
$FATEMed

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics (NASDAQ: FATE) said it will present preliminary Phase 1 basket-trial data for its off-the-shelf CD19 CAR T-cell FT819 in systemic sclerosis at the ISSCR 2026 meeting (July 8–11). As of June 12, four patients showed rCRISS25+ and mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.

manilatimes.net4 min
SEP 5
$SPWRHigh

SunPower Shares Fall 17.2% Following $26.2 Million Private Placement

SunPower Inc (SPWR) shares dropped 17.2% in pre-market trading after announcing a $26.2 million private placement at $0.2541 per share, below the previous close of $0.402. The deal adds 103.1 million shares, diluting existing shareholders. CEO T.J. Rodgers cited market changes and operational issues. SunPower had $4M in cash and negative equity at Q2 2026 end.

yahoo.com2 min